Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Raloxifene causing malabsorption of levothyroxine.

Siraj ES, Gupta MK, Reddy SS.

Arch Intern Med. 2003 Jun 9;163(11):1367-70.

PMID:
12796075
2.

Optimizing treatment of hypothyroidism.

Clarke N, Kabadi UM.

Treat Endocrinol. 2004;3(4):217-21. Review.

PMID:
16026104
3.

Use of soy protein supplement and resultant need for increased dose of levothyroxine.

Bell DS, Ovalle F.

Endocr Pract. 2001 May-Jun;7(3):193-4. Review.

PMID:
11421567
4.

Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment.

Laurberg P, Andersen S, Bülow Pedersen I, Carlé A.

Drugs Aging. 2005;22(1):23-38. Review.

PMID:
15663347
6.

Selective estrogen receptor modulators: raloxifene.

Rogowski A, Fidler B.

Med Health R I. 1999 Jan;82(1):29-30. Review. No abstract available.

PMID:
15600142
7.

Review on raloxifene: profile of a selective estrogen receptor modulator.

Heringa M.

Int J Clin Pharmacol Ther. 2003 Aug;41(8):331-45. Review.

PMID:
12940590
8.

[Primary hypothyroidism: Considerations for a rational use of levothyroxine therapy].

Bros JA, Lluís PG, Cabot GL, Pedragós AC.

Med Clin (Barc). 2011 Feb 26;136(5):207-14. doi: 10.1016/j.medcli.2009.05.022. Epub 2009 Jul 30. Review. Spanish. No abstract available.

PMID:
19646718
9.
10.

Levothyroxine absorption in health and disease, and new therapeutic perspectives.

Ianiro G, Mangiola F, Di Rienzo TA, Bibbò S, Franceschi F, Greco AV, Gasbarrini A.

Eur Rev Med Pharmacol Sci. 2014;18(4):451-6. Review.

11.

Levothyroxine in psychiatry: issues related to absorption after oral dosing.

Andrade C.

J Clin Psychiatry. 2013 Aug;74(8):e744-6. doi: 10.4088/JCP.13f08668. Review. No abstract available.

PMID:
24021514
12.

Conditions and drugs interfering with thyroxine absorption.

Liwanpo L, Hershman JM.

Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):781-92. doi: 10.1016/j.beem.2009.06.006. Review.

PMID:
19942153
13.

Raloxifene revisited.

Clarkson TB.

Fertil Steril. 2002 Mar;77(3):445-7. Review. No abstract available.

PMID:
11872191
14.

Alternative schedules of levothyroxine administration.

Geer M, Potter DM, Ulrich H.

Am J Health Syst Pharm. 2015 Mar 1;72(5):373-7. doi: 10.2146/ajhp140250. Review.

PMID:
25694412
15.

Molecular mechanism of action of selective estrogen receptor modulator in target tissues.

Ohmichi M, Tasaka K, Kurachi H, Murata Y.

Endocr J. 2005 Apr;52(2):161-7. Review. No abstract available.

16.

[Selective estrogen receptor modulator (SERM)].

Inoue D, Matsumoto T.

Nihon Rinsho. 2005 Mar;63 Suppl 3:613-8. Review. Japanese. No abstract available.

PMID:
15813137
17.

Liquid and softgel levothyroxine use in clinical practice: state of the art.

Virili C, Trimboli P, Romanelli F, Centanni M.

Endocrine. 2016 Oct;54(1):3-14. Epub 2016 Jul 29. Review.

PMID:
27473098
18.

Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review.

Skelin M, Lucijanić T, Amidžić Klarić D, Rešić A, Bakula M, Liberati-Čizmek AM, Gharib H, Rahelić D.

Clin Ther. 2017 Feb;39(2):378-403. doi: 10.1016/j.clinthera.2017.01.005. Epub 2017 Jan 30. Review.

PMID:
28153426
19.

Liquid levothyroxine and its potential use.

Formenti AM, Daffini L, Pirola I, Gandossi E, Cristiano A, Cappelli C.

Hormones (Athens). 2015 Apr-Jun;14(2):183-9. doi: 10.14310/horm.2002.1579. Review. No abstract available.

Supplemental Content

Support Center